RxDoctor Payments Data

Hamid Bashir, MD

Rheumatology · Janesville, WINPI 1225257694

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 79.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $4,012 and has fallen 78.7% since, to $853 in 2023.

$8,641in general payments, 2019–2025

Across 111 payments — averaging $77.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • AbbVie$409
  • Amgen$352
  • Novartis$349
  • UCB, Inc.$249
  • Lilly USA, LLC$131
  • plus $323 from 5 others

What the payments were for

  • Consulting fees$3,16537%
  • Speaking & faculty fees$1,85021%
  • Travel & lodging$1,00612%
  • Food & beverage$2,62030%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer30$6,827
AbbVie19$409
Amgen(2 entities)14$352
Novartis16$349
UCB, Inc.7$249
Lilly USA, LLC7$131
Boehringer Ingelheim5$104
AstraZeneca5$82
Sanofi3$59
GSK3$45
Sandoz2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,641 in reported general payments places this provider in the 85th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$30,433
Medicare patients
174
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$311,910
Xeljanz XrTofacitinib Citrate19$127,676
KevzaraSarilumab17$71,943
Leflunomide131$7,613
Hydroxychloroquine Sulfate178$5,525
MethotrexateMethotrexate Sodium175$4,488
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen111$1,853
Diclofenac Sodium32$1,622
Mycophenolate Mofetil15$1,561
Prednisone289$1,460
Pilocarpine Hcl13$1,149
Celecoxib42$1,113
Duloxetine Hcl40$539
Sulfasalazine16$535
Gabapentin22$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiKevzara$59$71,94317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 rheumatology providers in Wisconsin.

Other rheumatology in Janesville

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →